**Abstract**

**Background:** Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies.The long-term safety and tolerability of adjunctive treatment with brexpiprazole were evaluated in patients with major depressive disorder and inadequate response to antidepressant treatments, based on pooled data from two open-label extension studies.

**Methods:** These were open-label, 52- and 26-week, flexible-dose studies (study 1 \[NCT01447576\]: 0.25-3mg/day; study 2 \[NCT01360866\]: 0.5-3mg/day) with brexpiprazole. Study 1 enrolled de novo patients and patients completing one of the two phase II studies (NCT00797966; NCT01052077) while study 2 enrolled patients completing one of the two pivotal phase III studies (NCT01360645 \[1\];NCT01360632 \[2\]). Study 2 is still ongoing; data presented are based on a data-cut from 15-May-2015.

**Results:** 2084 patients were enrolled (697 from study 1 and 1387 from study 2); 48.8% (1016/2084) completed 52 weeks of treatment. Mean brexpiprazole dose was 1.6 mg/day. 13.9% (291/2084) of the patients had a TEAE leading to withdrawal; most frequent AEs leading to withdrawal (\>1%) were weight increased (3.6%) and depression (1.3%). The two most frequently reported AEs were weight increased (25.5%) and akathisia (10.0%); the AE profile was similar to that observed in the short-term lead-in studies with no indication of an increased incidence over time for any AEs. Mean weight gain was 2.9kg at week 26 (n=1259) and 3.2kg at week 52 (n=1015). 30.3% (629/2077)of patients had a weight increase that was ≥7% in body weight. There were small changes in other metabolic parameters.

**Conclusion:** Long-term adjunctive treatment with brexpiprazole was safe and well tolerated. Although increases in body weight were observed over time for some patients, the low incidence of discontinuation among those patients suggests that the weight gain was not treatment-limiting for most patients.
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